Article citationsMore>>

FDA, “FDA PAT Page.”
http://www.fda.gov/cder/OPS/PAT.htm

has been cited by the following article:

• TITLE: The Polymorphism and Transformation of (3aRS, 4RS, 7RS, 7aSR)-2-(Tricyclo[3.3.1.13,7]decan-1-yl)-4,5,6,7-tetrahydro-4,7-eposyisoindoline-1,3-dione (SU2162)—A Novel Anticancer Compound

  AUTHORS: Yuqing Huang, Zaiyou Tan, Lin Luo, Hui Yang, Chunmei Tong, Wenfei Chen, Tingyu Huang, Ruiling Liu

  KEYWORDS: SU2162; Polymorphism; Crystal Form; Melting Method; Solvent Method

  JOURNAL NAME: Journal of Crystallization Process and Technology, Vol.4 No.1, January 8, 2014

  ABSTRACT: Objective: To determine the transformation between two known crystal forms of the title compound (C18H23NO3, Mr = 301.37). Methods: To recrystallize or heat the crystals and determine the crystal form by testing the melting points. Results: Both the two known crystal forms of the title compound can be changed by dissolving into different organic solvents such as acetone and ethyl acetate. Crystal form I was not influenced by heating while crystal form II can be transformed to crystal form I through melting method. Conclusion: Organic solvents have significant influences on the two crystal forms of title compound. Crystal form I shows a better thermal stability than crystal form II.